152 completed, 79 unknown, 56 recruiting, 56 terminated. 243 Phase 2, 187 Phase 1, 54 Phase 3, 9 Phase 4, 8 Not applicable.
Follow this drug Literature Review of Decitabine trials Research Report on Decitabine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML Decitabine, Venetoclax, Axatilimab - Acute Myeloid Leukemia, TP53 Gene Mutation | Phase 1 | Not yet recruiting | Northside Hospital, Inc. | 32 | 2027-01-31 | 2026-10-16 |
| Research for Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-MDS) in the Treatment of Myelodysplastic Syndrome (MDS) Allogeneic umbilical cord mesenchymal stem cells, Decitabine - Myelodysplastic Syndromes | Phase 1 / Phase 2 | Suspended | Sclnow Biotechnology Co., Ltd. | 40 | 2026-12-31 | 2026-04-23 |
| Phase II De-Escalation Study of Metronomic Decitabine/Cedazuridine Plus Venetoclax in AML Venetoclax, Decitabine/Cedaruridine, decitabine/cedazuridine - Acute Myeloid Leukaemia (AML) | Phase 2 | Not yet recruiting | Rutgers, The State University of New Jersey | 41 | 2026-09-30 | 2026-10-09 |
| A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies. Decitabine, Cyclophosphamide Conditioning, NY-ESO-1 TCR/ dnTGFβRII - Ovarian Cancer, Advanced Malignant Solid Tumor | Phase 1 / Phase 2 | Recruiting | University of Chicago | 24 | 2026-09-09 | 2026-10-13 |
| ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS ATRN-119, Decitabine - Acute Myeloid Leukemia, High-risk Myelodysplastic Syndrome | Phase 1 | Not yet recruiting | Washington University School of Medicine | 27 | 2026-08-31 | 2026-06-01 |
| A Study of VABu Conditioning Regimen in Allo-HSCT for AML Patients Venetoclax, Azacitidine (AZA), Decitabine 20 mg/m²/day for 5 days - Leukemia, Myeloid, Acute(AML), Hematopoietic Stem Cell Transplantation (HSCT) | Not applicable | Not yet recruiting | The First Affiliated Hospital of Soochow University | 42 | 2026-08-01 | 2026-08-19 |
| New Genotype-guided Treatment in Newly Diagnosed PTCL Azacitidine plus Selinexor with CHOP, Decitabine plus Selinexor with CHOP, Zeprumetostat plus chidamide with CHOP - Peripheral T-cell Lymphoma (PTCL) | Phase 1 / Phase 2 | Not yet recruiting | Ruijin Hospital | 108 | 2026-07-01 | 2026-07-16 |
| Serplulimab Plus Decitabine and CAPOX Before Surgery for Locally Advanced Colorectal Cancer Serplulimab + Decitabine + CAPOX (Oxaliplatin + Capecitabine) - Locally Advanced Colorectal Cancer, Colorectal Adenocarcinoma | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 35 | 2026-06-30 | 2026-07-09 |
| Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML Patients Decitabine/Cedazuridine 35 Mg-100 Mg ORAL TABLET, Ivosidenib Oral Tablet, Hydroxyurea - Acute Myeloid Leukemia With Gene Mutations | Phase 2 | Recruiting | PETHEMA Foundation | 50 | 2026-06-12 | 2026-09-22 |
| A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia | Phase 1 | Recruiting | National Cancer Institute (NCI) | 47 | 2026-06-09 | 2026-10-19 |
| AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL Polatuzumab Vedotin, rituximab, Cyclophosphamide - Large B-Cell Lymphoma (LBCL) | Phase 2 | Not yet recruiting | Ruijin Hospital | 178 | 2026-05-06 | 2026-05-19 |
| Modulation of Stem Cell Differentiation in Individuals With High Risk Clonal Haematopoiesis Oral Decitabine and Tetrahydrouridine, Matched Placebo (Capsules) - Clonal Cytopenia of Uncertain Significance, CCUS Clonal Cytopenia of Undetermined Significance | Phase 2 | Not yet recruiting | Clinical Hub for Interventional Research (CHOIR) | 80 | 2026-04-13 | 2026-02-27 |
| Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker 5hmC Biomarker, Venetoclax, Decitabine 20 mg/m²/day for 5 days - Acute Myeloid Leukemia (AML), Acute Myeloid Leukaemia (AML) | Phase 2 | Recruiting | The Methodist Hospital Research Institute | 112 | 2026-04-09 | 2026-10-08 |
| Evaluating the Safety and Efficacy of Decitabine in the Treatment of XMEN Patients Decitabine - MAGT1 Deficiency | Phase 4 | Not yet recruiting | Children's Hospital of Fudan University | 6 | 2026-04-01 | 2026-04-29 |
| High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML) Azacitidine, Venetoclax, High-dose ascorbate - Acute Myeloid Leukemia | Phase 1 | Recruiting | Kittika Poonsombudlert | 30 | 2026-03-18 | 2026-08-31 |
| Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms Pacritinib, Decitabine, Decitabine and Cedazuridine - Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm | Phase 2 | Recruiting | University of Washington | 27 | 2026-03-02 | 2026-08-19 |
| Efficacy and Safety of Lisafotoclax Plus Decitabine and Homoharringtonine in Venetoclax/Azacitidine Pretreated AML Patients Lisafotoclax, Decitabine, Homoharringtonine - Acute Myeloid Leukemia (AML) | Phase 2 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 35 | 2026-03-01 | 2026-04-01 |
| Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML DC/AML Fusion Vaccine, T-Cell Therapy, Decitabine - Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse | Phase 1 | Recruiting | David Avigan | 30 | 2026-02-12 | 2026-05-05 |
| FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia Decitabine, Venetoclax, FHD-286 - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Recruiting | Montefiore Medical Center | 33 | 2026-02-03 | 2026-03-03 |
| Decitabine in Combination With Standard of Care Therapy for the Treatment of Surgically Resectable HPV-Negative Head and Neck Cancer Biospecimen Collection, Chemotherapy, Decitabine - Human Papillomavirus-Negative Neck Squamous Cell Carcinoma, Resectable Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | Mayo Clinic | 32 | 2026-01-23 | 2026-07-15 |
Showing 20 of 418. Sign in to see all of them.
Leukemia, Myeloid, Acute (190) · Myelodysplastic Syndromes (113) · Leukemia (39) · Leukemia, Myelomonocytic, Chronic (36) · Recurrence (27) · Congenital Abnormalities (16) · Myeloproliferative Disorders (15) · Lymphoma, Large B-Cell, Diffuse (13) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (13) · Neoplasms (11) · Primary Myelofibrosis (10) · Blast Crisis (9) · Melanoma (9) · Anemia, Refractory, with Excess of Blasts (7) · Carcinoma, Non-Small-Cell Lung (7)
M.D. Anderson Cancer Center (41) · National Cancer Institute (NCI) (33) · Chinese PLA General Hospital (19) · The First Affiliated Hospital of Soochow University (15) · Ruijin Hospital (12) · Eisai Inc. (9) · Nanfang Hospital, Southern Medical University (9) · Washington University School of Medicine (8) · Astex Pharmaceuticals, Inc. (7) · Roswell Park Cancer Institute (7) · Fred Hutchinson Cancer Center (6) · City of Hope Medical Center (5) · Mayo Clinic (5) · Novartis Pharmaceuticals (5) · Beijing 302 Hospital (4)
United States (251) · China (101) · Canada (22) · Germany (22) · Italy (18) · Spain (15) · France (14) · Australia (12) · United Kingdom (12) · Belgium (10) · South Korea (10) · Netherlands (9) · Poland (8) · Hungary (6) · Taiwan (6)
Qifa Liu (8) · Courtney DiNardo, MD (3) · David S Schrump, M.D. (3) · Mohammed Milhem, MD (3) · William Blum (3) · Anna Halpern (2) · Aref Al-Kali (2) · Bhavana Bhatnagar, DO (2) · Carlos de Castro, MD (2) · Cynthia A Zamora, MD (2) · David Avigan, MD (2)
PMID 31039052, PMID 17679729, PMID 20368434, PMID 20564122, PMID 23260600, PMID 23660685, PMID 23790798, PMID 25566808, PMID 33646303, PMID 33674274, PMID 33820822, PMID 34255353, PMID 36184192, PMID 39133921, PMID 39863139, PMID 10623705, PMID 10655437, PMID 10694544, PMID 10830142, PMID 11085525, PMID 12393992, PMID 14673054, PMID 15273730, PMID 15374957, PMID 15542813, PMID 15547525, PMID 15641020, PMID 16818281, PMID 16882711, PMID 1695122, PMID 17038533, PMID 17320506, PMID 17336087, PMID 17512352, PMID 17925555, PMID 18055864, PMID 18234305, PMID 18596741, PMID 18826610, PMID 19005182, PMID 19110234, PMID 19151774, PMID 19752007, PMID 19773261, PMID 20495664, PMID 20564154, PMID 20602996, PMID 20668231, PMID 20876310, PMID 20944599
U01CA076576 (6), P30CA015704 (5), P30CA033572 (5), 2015 (4), P30CA016672 (4), N01CM62207 (3), P30CA015083 (3), P30CA016056 (3), P30CA016058 (3), 2014 (2), 2016 (2), 2018 (2), P50CA171963 (2), U01CA062461 (2), U01CA097452 (2)